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OBJECTIVES: The aim of this study was to report the type and frequency of ocular manifestations in Brazilian
psoriatic arthritis patients.
METHODS: We conducted a cross-sectional study in a Brazilian tertiary hospital. The test group included 40 patients
who had psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis. A control group of 40
individuals was matched for age and gender. All of the patients underwent ophthalmic evaluation, which included
best-corrected visual acuity, slit lamp and fundus examinations, and dry eye diagnostic tests (Schirmer I, tear break-
up time and rose bengal). Demographic parameters were also evaluated.
RESULTS: The mean age of the patients was 53.9¡13.1 years; the mean disease duration was 8¡10.5 years. Most of
the patients were women (60%), and the majority had polyarticular disease (57.5%). Several ocular abnormalities
were found, including punctate keratitis, pinguecula, blepharitis, pterygium, cataract, glaucoma, uveitis, and retinal
microvascular abnormalities. There were no significant differences in the rates of these abnormalities compared
with the control group, however. The Keratoconjunctivitis sicca and dry eye diagnostic tests were more often
positive in the patients with psoriatic arthritis than in the control group.
CONCLUSIONS: In this study, keratoconjunctivitis sicca was the most common ocular finding related to psoriatic
arthritis. Therefore, we recommend early ophthalmologic evaluations for all psoriatic arthritis patients who
complain of eye symptoms.
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INTRODUCTION
Psoriatic arthritis (PsA) is an inflammatory arthritis
associated with psoriasis. Skin lesions are typically the first
signs of the disease, followed by the articular manifesta-
tions. The articular manifestations may occur first in rare
cases, however (1).
Psoriasis is a chronic, immunologically mediated disease
with both genetic and environmental risk factors. It affects 1 to
3% of the world’s population. Arthritis occurs in up to 30% of
the patients with psoriasis, and it is diagnosed based on
clinical and radiological features (2,3). The inflammatory
arthritis associated with psoriasis is typically seronegative for
rheumatoid factor and exhibits a variety of disease patterns,
including oligoarticular disease, polyarticular disease, distal
interphalangeal disease (IFD), arthritis mutilans, and axial
disease (4).
The seronegative spondyloarthropathies, including PsA,
are a group of disorders that share many clinical and
pathologic features (5). The HLA-B27 antigen is found in
some patients with PsA, and this antigen can be used as a
prognostic marker for clinical disease progression (6). HLA-
B27 is associated with earlier onset of psoriatic arthritis and
bilateral sacroiliitis and is more common in men.
An ocular inflammatory reaction is commonly found in
many rheumatologic diseases (7), and there are various
ocular disorders associated with psoriatic arthritis. These
disorders include abnormalities of the conjunctiva, cornea,
sclera, uvea, and lens. To date, there are no significant
publications exploring the prevalence of eye disease in
patients with psoriatic arthritis (8).
The aim of this study was to report the ocular manifesta-
tions of the psoriatic arthritis patients seen at a university
hospital in Brazil.
METHODS
This cross-sectional study included outpatients with PsA
seen at the university hospital of the Federal University of
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249Rio de Janeiro, Brazil, from March 2010 to October 2010. This
study was approved by the Medical Ethics Committee
of the hospital. Before enrollment, all of the patients pro-
vided informed consent in accordance with the Helsinki
Declaration.
The test group consisted of 40 patients who had been
diagnosed with PsA according to the Classification Criteria
for Psoriatic Arthritis (CASPAR) and who were being
treated by the Rheumatology Unit (9).
The control group consisted of 40 patients without PsA
who were recruited from the Primary Care Unit. To avoid
clinical and statistical bias, these patients were selected and
matched for age and gender.
In both groups, we excluded the patients younger than 18
years of age and those with inflammatory connective tissue
diseases, nephropathy, lung and heart disease, gastroenter-
ological disease/inflammatory bowel disease, neurological
disease, neoplasia, metabolic bone disease, skin diseases
(except psoriasis), infections, hematological disease, liver
disease, previous ocular surgery, active eye infection, active
ocular allergy, and evidence of an abnormal eyelid move-
ment disorder.
We also recorded other patient characteristics, including
age, gender, history of systemic hypertension or diabetes,
and use of topical eye medications, for the cases and
controls. The disease duration and use of systemic PsA
medications were also recorded for the patients in the case
group.
The patients were not permitted to use artificial tears
within 2 hours of the screening evaluation.
One ophthalmologist performed all of the ophthalmic
exams in sequential order.
First, the best-corrected visual acuity (BCVA) was
measured using the Snellen chart.
Second, a slit lamp examination was used to evaluate
the cornea for the presence of active inflammation and
structural changes at a magnification of 10X to 16X. A
cataract evaluation was performed according to the Lens
Opacities Classification System III (10).
Third, the tear break-up time (TBUT), Schirmer I and rose
bengal staining tests were used sequentially to detect dry
eyes. To perform the TBUT, 1% fluorescein (Fludiag,
Oftalmopharma, Sao Paulo, Brazil) was applied to the
eye, and the average of three consecutive breakup times
(manually determined with a stopwatch) was calculated. A
time of ,10 seconds was considered abnormal. The
Schirmer I test was performed by applying a 5635 mm
paper strip (Schirmer strips, Ophthalmos, Sao Paulo, Brazil)
without anesthesia to the lower temporal lid margin; values
of ,10 mm in 5 minutes were considered to be abnormal.
These cutoff values were based on the normal reference
values described in the literature (11). The inferior bulbar
conjunctiva was touched with a rose bengal strip (rose
bengal strips, Ophthalmos, Sa ˜o Paulo, Brazil) to assess
staining. The reaction was classified according to the van
Bijsterveld Scoring System and values .3 were considered
to be abnormal (12). For each sign, the most extreme
measurement was used in the analysis.
The Japanese criteria for dry eyes, which include
symptom evaluation, the Schirmer I or TBUT tests, and
rose bengal staining, were applied (13). For a definitive
diagnosis, the patient needed to have had symptoms and
two positive tests. The patients who met only two criteria
were classified as having probable dry eye.
The Ocular Surface Disease Index (OSDI) questionnaire
was administered to assess the ocular dry eye symptoms
(14).
Intraocular pressure was measured using Goldmann
applanation tonometry. Values .21 mmHg were consid-
ered to be abnormal. A diagnosis of open-angle glaucoma
was based on visual field, gonioscopic, and optic nerve
abnormalities (15).
Fundoscopy was performed using indirect ophthalmo-
scopy with a 20-diopter Volk lens.
Statistical Analysis
Due to the need for consistency, patients (rather than
affected eyes) were matched when choosing the control
group. The descriptive data are presented in tables and are
expressed by frequency (n) and percentage (%) for
categorical data and the mean ¡ SD (or median ¡ IQR)
for numerical data.
To compare the numerical data, we used the Student’s t-
test for normally distributed data or the Mann-Whitney test
for non-normally distributed data. We used the x2 test or
Fisher’s exact test for comparisons of categorical data.
The nonparametric method was used because some
variables did not have a normal (Gaussian) distribution
due to large dispersion (the hypothesis of normality was
rejected in the Kolmogorov-Smirnov test).
The significance level was set at p,0.05. Statistical analyses
were performed using the SAS H version 6.11 statistical
software (SAS Institute Inc., Cary, North Carolina).
RESULTS
In total, 40 PsA patients were evaluated. The mean age of
the PsA patients was 53.9¡13.1 years, and 24 (60%) were
female. The mean disease duration was 8¡10.5 years. The
demographic data are shown in Table 1. Polyarticular
disease was the most common disease characteristic (57.5%).
Majority of patients were taking medications for PsA: 27
patients (67.5%) were using methotrexate, 17 patients
(42.5%) were using oral corticosteroids, 13 patients (32.5%)
were using tumor necrosis factor alpha receptor antagonists
(anti-TNF), and three patients (7.5%) were using anti-
malarial medications.
Of the four patients with glaucoma, three were using
timolol maleate 0.5%, and one was using brimonidine
tartrate 0.2%. In addition, four other patients were using
artificial tears.
Table 1 - Demographic data by group.
Arthritis
(n=40)
Control
(n=40) p-value
n%n%
Age (y) * 53.9¡13.1 58.6¡12.5 0.10
Female gender 24 60.0 24 60.0 1.0
Diabetes 7 17.5 5 12.5 0.53
Systemic Hypertension 17 42.5 12 30.0 0.24
Mean duration of disease (y) 8¡10.5 NS NS
*Age was expressed as the mean ¡ standard deviation and data were
analyzed with the Student’s t-test for independent samples.
The x2 test was used to compare proportions (categorical data).
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250The majority of the patients (90% in the study group and
85% the control group) presented with a BCVA of 0.66 or
better. The remaining patients had BCVAs of 0.25 or worse
in at least one eye. The low visual acuity was bilateral and
was caused by nuclear cataracts in all of these patients.
Several ocular abnormalities were found upon biomicro-
scopy and fundoscopy evaluation. Using the data from our
control group, we were able to correlate the large number of
ocular abnormalities with PsA. With the exception of
pterygium and uveitis, the frequency and type of ophthal-
mologic findings (glaucoma, cataract, blepharitis, pingue-
cula, punctate keratitis, and retinal microvascular
abnormalities) did not differ significantly between the case
and control groups. There were not enough cases of
pterygium and uveitis to make comparisons between the
groups. These findings are summarized in Table 2.
It is also important to note that all of the cataracts were
age related, the glaucoma cases were all classified as
primary open-angle glaucoma and all of the patients who
presented with retinal microvascular abnormalities also
presented with systemic hypertension.
All of the uveitis cases appeared to be anterior uveitis in
which there were posterior and anterior synechias and
corneal endothelium changes but no fundal involvement.
Both of the uveitis cases were observed in patients with
oligoarticular arthritis.
The mean intra-ocular pressures for all of the patients,
including those with glaucoma, were 13.0¡1.7 in the right
eyes and 13.1¡1.8 in the left eyes. These relatively normal
values were most likely due to the patients with glaucoma
taking medications.
Ocular tests were used to test for KCS. In the PsA group,
we found 27 patients (67.5%) with abnormal TBUTs, 20
patients (50%) with abnormal Schirmer I tests, and 11
patients (27.5%) with abnormal rose bengal tests; all of these
tests were significantly more likely to be positive in the PsA
group. Nine patients (22.5%) in the PsA group were
symptomatic and tested positive on the OSDI. However,
these results were not significantly different from those of
the control group. According to the criteria adopted in this
study, 6 PsA patients (15%) had a definitive diagnosis and 9
(22.5%) had a probable diagnosis of KCS (p,0.05 for both).
In addition, the mean TBUT, Schirmer and rose bengal
values were calculated and described in Table 3. Most of
the patients in the definitive and probable KCS groups
presented with oligoarthritis and/or polyarticular disease,
and the majority were using methotrexate for disease
control.
The demographic parameters are shown in Table 1.
In the control group, three patients were using timolol
maleate 0.5%, and two patients were using artificial tears.
DISCUSSION
This study represents the largest group of Brazilian
psoriatic arthritis patients who have been screened for
associated ocular manifestations.
Polyarthritis was the most common PsA presentation in
this study. Some researchers have concluded that oligoar-
thritis is the most common manifestation of PsA, whereas
some have claimed that polyarthritis is more common (16).
Overlapping PsA articular subtypes are common over time,
and the distributions may vary as different definitions are
applied. Similarly, patterns change over time due to
increases in disease duration and changes in natural history
that may lead patients to develop a polyarticular pattern
(17).
According to the results presented here, PsA patients
frequently develop ocular inflammatory conditions. Previous
studies have shown that PsA patients may present with
conjunctivitis, uveitis, and KCS (18). We did not find any
patients with conjunctivitis because we specifically selected
patients who visited the department of rheumatology for
treatment.
Uveitis is an important ocular abnormality that is
described in PsA patients (19). The frequency of uveitis
associated with psoriatic arthritis ranges from 0.4 to 18%
(20-22). In this study, 5% of the patients exhibited signs of
uveitis, which was classified as anterior, unilateral and
acute. In general, these signs are classically associated with
spondyloarthropathies and are not specifically related to
PsA. (23). It is important to emphasize that these patients
Table 2 - Ocular findings by group.
Arthritis
(n=40)
Control
(n=40) p-value
n%n%
Visual Acuity $0.66 36 90.0 34 85.0 0.49
Glaucoma 4 10.0 3 7.5 0.50
Cataract 4 10.0 8 20.0 0.21
Blepharitis 5 12.5 9 22.5 0.23
Punctate keratitis 9 22.5 4 10.0 0.13
Pinguecula 8 20.0 9 22.5 0.78
Pterygium 2 5.0 2 5.0 fc
Uveitis 2 5.0 0 0.0 fc
Microvascular abnormalities 6 15 4 10 0.49
IOP right eye (mmHg) * 13.0¡1.7 13.2¡2.2 0.73
IOP left eye (mmHg) * 13.1¡1.8 13.0¡2.1 0.86
fc: fewer than 5 cases.
*IOP was expressed as the mean ¡ SD and analyzed using the Student’s t-
test for independent samples. The x2 test or Fisher’s exact test was used
to compare proportions (categorical data).
Table 3 - KCS features by group.
Arthritis
(n=40)
Control
(n=40) p-value
n%n%
OSDI 9 22.5 5 12.5 0.23
KCS 6 15 1 2.5 0.05
Probable KCS 9 22.5 2 5 0.023
TBUT 27 67.5 11 27.5 ,0.0001
ROSE BENGAL 11 27.5 4 10 0.045
SCHIRMER 20 50 7 17.5 0.002
TBUT right eye (s) * 8¡51 1 ¡2.5 0.0001
TBUT left eye (s) * 8¡51 1 ¡3 0.0001
ROSE BENGAL right eye
(points) *
2¡21 ¡2 0.0015
ROSE BENGAL left eye
(points) *
1¡21 ¡1.5 0.002
SCHIRMER right eye (mm) * 10¡9.5 14¡5 0.004
SCHIRMER left eye (mm) * 10¡11 15¡5 0.005
*The numerical KCS measurements were expressed as the median ¡ IQR
and analyzed using the Mann-Whitney (nonparametric) test.
The x2 test or Fisher’s exact test were used to compare proportions
(categorical data).
OSDI: Ocular Surface Disease Index; KCS: Keratoconjunctivitis Sicca; TBUT:
Tear Break-up Time.
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251were not using anti-TNF-alpha medications because these
agents may induce paradoxical uveitis in patients with
rheumatic diseases (24,25).
In this study, we found a high number of abnormal dry
eye tests in the PsA patients. Many of these patients met the
European classification criteria for Sjogren’s syndrome (26),
and we believe that these results demonstrate the presence
of important ocular SS signs in this study group. The
presence of SS in patients with spondyloarthropathies has
been corroborated by the literature (27).
We also found that 15% of the PsA patients met the
criteria for KCS and that another 22.5% had probable KCS.
This rate may be underestimated because we used rigid
diagnostic criteria. Furthermore, the disease may have been
misclassified, particularly in the early stages when the
typical signs and symptoms are less clear. There is a poor
relationship between the signs and symptoms of dry eye
(28). Therefore, these data are important because KCS is
well recognized in other rheumatologic diseases, such as
rheumatoid arthritis (29,30).
Blepharitis, pterygium, pinguecula, and keratitis are
ophthalmic conditions commonly found in the general
population (31,32,33). Our study showed a high frequency
of these findings in the PsA patients. However, these rates
did not differ markedly from the data in the literature or
from the control group.
Most of the patients in this study presented with good
visual acuity. Cataracts were responsible for most of the
visual impairment. All of these patients presented with the
age-related nuclear cataract subtype, which differs from
cataracts caused by uveitis or steroid use (34).
Our study group had a higher prevalence (10%) of
primary open-angle glaucoma than that of the general
population (0.8 a 3.0%) (15). We observed no signs of
glaucoma secondary to uveitis or steroid use, which is the
type of glaucoma more commonly found in rheumatologic
diseases (35). Moreover, there were no significant differ-
ences between the two groups in the number of glaucoma
diagnoses or average intraocular pressure values.
In this study, 15% of the patients had micro-vascular
retinal abnormalities that were indistinguishable from those
related to systemic hypertension. There were no significant
differences between the two groups (36,37).
High levels of TNF-alpha are found in the joint fluid and
tissue of patients with psoriatic arthritis. TNF-alpha induces
the production of other pro-inflammatory cytokines that
mediate multiple biological processes responsible for joint
damage (38). A clinical trial of etanercept provided strong
evidence that this medication is effective for psoriatic
arthritis (39). The efficacy of anti-TNF agents for patients
with uveitis and scleritis has been observed in a limited
study, but anti-TNF treatment has caused both improve-
ment and exacerbation of inflammatory eye disease (40).
Another author has shown that Infliximab was effective for
suppressing intraocular inflammation; the clinical symp-
toms improved significantly, and anterior chamber cells
decreased rapidly (41). These findings may explain why the
patients in this study who were using anti-TNF agents
presented without uveitis or scleritis. The inflammatory
conditions that they presented with were not severe
(blepharitis and keratitis).
The retinal toxicity of antimalarial drugs, such as
chloroquine and hydroxychloroquine, has been recognized
for many years (42). No retinopathy was found in any of the
patients in this study.
The clinical efficacy of methotrexate for PsA is well known,
and the agent has beena mainstay of treatment for many years.
Methotrexate is associated severe adverse events, of which
liver toxicity is the most common. The patients in our study
maintained regular follow-ups with their rheumatologists; at
the conclusion of the study, our patients did not experience
any significant adverse events (43).
In conclusion, many ocular abnormalities were found
in the PsA patients, including cataracts, glaucoma, and
blepharitis. These findings were found in similar rates
in the control group. However, the increased rate of
Keratoconjunctivitis sicca in the PsA patients was statisti-
cally significant. This finding is important for understand-
ing the disease and for clinical management. Although
uveitis was not significantly more common in the PsA
group, it must be monitored in PsA patients due to its
clinical relevance.
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